Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 1,816,131 shares, a decrease of 26.2% from the February 26th total of 2,460,745 shares. Based on an average daily volume of 1,893,138 shares, the days-to-cover ratio is currently 1.0 days. Currently, 6.9% of the company’s shares are sold short.

Institutional Investors Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Marshall Wace LLP purchased a new position in MAIA Biotechnology during the second quarter valued at $29,000. Ritholtz Wealth Management bought a new stake in shares of MAIA Biotechnology during the 4th quarter valued at $35,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth about $52,000. Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the period. Finally, Centric Wealth Management increased its stake in shares of MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after acquiring an additional 11,500 shares in the last quarter. 5.65% of the stock is owned by hedge funds and other institutional investors.

MAIA Biotechnology Stock Down 5.1%

Shares of NYSEAMERICAN:MAIA traded down $0.07 on Friday, hitting $1.31. The company had a trading volume of 2,486,016 shares, compared to its average volume of 1,268,306. The firm’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.57. The firm has a market capitalization of $50.64 million, a price-to-earnings ratio of -1.90 and a beta of -0.04. MAIA Biotechnology has a 1 year low of $0.87 and a 1 year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. Equities research analysts anticipate that MAIA Biotechnology will post -1.3 EPS for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.